Skip to main content

Advertisement

SpringerLink
Log in

Stellenwert der stereotaktischen Radiotherapie für das nichtresezierte Pankreaskarzinom

Role of stereotactic body radiation therapy for unresected pancreatic cancer

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Chauffert B, Mornex F, Bonnetain F, et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5‑FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. https://doi.org/10.1093/annonc/mdn281

  2. Loehrer PJ Sr, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J Clin Oncol 29:4105–4112. https://doi.org/10.1200/JCO.2011.34.8904

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Hammel P, Huguet F, Van Laethem JL et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2016.4324

    Article  PubMed  Google Scholar 

  4. Herman JM, Chang DT, Goodman KA et al (2015) Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121(7):1128. https://doi.org/10.1002/cncr.29161

    Article  PubMed  CAS  Google Scholar 

  5. Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2009.08.020

    Article  PubMed Central  PubMed  Google Scholar 

  6. Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol (Madr) 45:823–830. https://doi.org/10.1080/02841860600904854

    Article  Google Scholar 

  7. Murphy JD, Christman-Skieller C, Kim J et al (2010) A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2009.09.075

    Article  PubMed  PubMed Central  Google Scholar 

  8. Brunner TB, Nestle U, Grosu A‑L, Partridge M (2015) Systematic review SBRT in pancreatic cancer: what is the therapeutic window? Radiother Oncol 114:109–116. https://doi.org/10.1016/j.radonc.2014.10.015

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radio-Onkologie, Universitätsspital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz

    Jana Heitmann &  Matthias Guckenberger

Authors
  1. Jana Heitmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Guckenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jana Heitmann or Matthias Guckenberger.

Ethics declarations

Interessenkonflikt

J. Heitmann und M. Guckenberger geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

de Geus SWL, Eskander MF, Kasumova GG et al (2017) Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer 123(21):4158–4167

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heitmann, J., Guckenberger, M. Stellenwert der stereotaktischen Radiotherapie für das nichtresezierte Pankreaskarzinom. Strahlenther Onkol 194, 867–869 (2018). https://doi.org/10.1007/s00066-018-1331-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-018-1331-1

Search

Navigation